Detailed Information
Cited 1 time in 
Cited 0 time in 
Cited 0 time in
Metadata Downloads
Efficacy and safety of lenvatinib (LEN) plus pembrolizumab (PEMBRO) versus sunitinib (SUN) in the East Asian subset of patients with advanced renal cell carcinoma (aRCC) from the phase 3 CLEAR trial.
- Authors
- Rha, SY[Rha, Sun Young]; Choueiri, TK[Choueiri, Toni K.]; Matveev, VB[Matveev, Vsevolod B.]; Alyasova, A[Alyasova, Anna]; Hong, SH[Hong, Sung-Hoo]; Gordoa, TA[Gordoa, Teresa Alonso]; Gurney, H[Gurney, Howard]; Bjarnason, GA[Bjarnason, Georg A.]; Buchler, T[Buchler, Tomas]; Pedrazzoli, P[Pedrazzoli, Paolo]; Takagi, T[Takagi, Toshio]; Park, SH[Park, Se Hoon]; Lee, JL[Lee, Jae-Lyun]; Perini, RF[Perini, Rodolfo F.]; He, CX[He, Cixin]; McKenzie, JA[McKenzie, Jodi A.]; Eto, M[Eto, Masatoshi]
- Issue Date
- 20-Feb-2022
- Publisher
- LIPPINCOTT WILLIAMS & WILKINS
- Citation
- JOURNAL OF CLINICAL ONCOLOGY, v.40, no.6
- Indexed
- SCIE
SCOPUS
- Journal Title
- JOURNAL OF CLINICAL ONCOLOGY
- Volume
- 40
- Number
- 6
- ISSN
- 0732-183X
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - Medicine > Department of Medicine > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.